Beyond Cost: What Manufacturers Look for in Investment Locations

For decades, the global pharmaceutical industry operated on a singular priority: optimize supply chains for maximum efficiency. The just-in-time manufacturing model kept inventories lean and production centralized, all in service of a stable global supply chain.

Then COVID hit, and a perfect storm of macroeconomic and geopolitical pressures upended that paradigm. Since the pandemic, organizations have shifted toward a multinational approach — spreading manufacturing across regions to build resilience. That shift requires a refreshed view on location selection, talent, and technology.

Intensifying geopolitical concerns and unpredictable regulatory and pricing volatility mean manufacturers now need supply chains built for regionalized hubs, balancing operational flexibility with geographical security — all while managing cost. Navigating that transition means building ecosystems designed to absorb macro shocks without upending supply stability.